BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32681751)

  • 1. Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions.
    Ng BG; Eklund EA; Shiryaev SA; Dong YY; Abbott MA; Asteggiano C; Bamshad MJ; Barr E; Bernstein JA; Chelakkadan S; Christodoulou J; Chung WK; Ciliberto MA; Cousin J; Gardiner F; Ghosh S; Graf WD; Grunewald S; Hammond K; Hauser NS; Hoganson GE; Houck KM; Kohler JN; Morava E; Larson AA; Liu P; Madathil S; McCormack C; Meeks NJL; Miller R; Monaghan KG; Nickerson DA; Palculict TB; Papazoglu GM; Pletcher BA; Scheffer IE; Schenone AB; Schnur RE; Si Y; Rowe LJ; Serrano Russi AH; Russo RS; Thabet F; Tuite A; Villanueva MM; Wang RY; Webster RI; Wilson D; Zalan A; ; Wolfe LA; Rosenfeld JA; Rhodes L; Freeze HH
    J Inherit Metab Dis; 2020 Nov; 43(6):1333-1348. PubMed ID: 32681751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exome sequence identified a c.320A > G ALG13 variant in a female with infantile epileptic encephalopathy with normal glycosylation and random X inactivation: Review of the literature.
    Hamici S; Bastaki F; Khalifa M
    Eur J Med Genet; 2017 Oct; 60(10):541-547. PubMed ID: 28778787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALG13 X-linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes.
    Alsharhan H; He M; Edmondson AC; Daniel EJP; Chen J; Donald T; Bakhtiari S; Amor DJ; Jones EA; Vassallo G; Vincent M; Cogné B; Deb W; Werners AH; Jin SC; Bilguvar K; Christodoulou J; Webster RI; Yearwood KR; Ng BG; Freeze HH; Kruer MC; Li D; Raymond KM; Bhoj EJ; Sobering AK
    J Inherit Metab Dis; 2021 Jul; 44(4):1001-1012. PubMed ID: 33734437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phenotypic spectrum of X-linked, infantile onset ALG13-related developmental and epileptic encephalopathy.
    Datta AN; Bahi-Buisson N; Bienvenu T; Buerki SE; Gardiner F; Cross JH; Heron B; Kaminska A; Korff CM; Lepine A; Lesca G; McTague A; Mefford HC; Mignot C; Milh M; Piton A; Pressler RM; Ruf S; Sadleir LG; de Saint Martin A; Van Gassen K; Verbeek NE; Ville D; Villeneuve N; Zacher P; Scheffer IE; Lemke JR
    Epilepsia; 2021 Feb; 62(2):325-334. PubMed ID: 33410528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALG13-Congenital Disorder of Glycosylation (ALG13-CDG): Updated clinical and molecular review and clinical management guidelines.
    Shah R; Eklund EA; Radenkovic S; Sadek M; Shammas I; Verberkmoes S; Ng BG; Freeze HH; Edmondson AC; He M; Kozicz T; Altassan R; Morava E
    Mol Genet Metab; 2024 Jun; 142(2):108472. PubMed ID: 38703411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALG13-CDG with Infantile Spasms in a Male Patient Due to a De Novo ALG13 Gene Mutation.
    Galama WH; Verhaagen-van den Akker SLJ; Lefeber DJ; Feenstra I; Verrips A
    JIMD Rep; 2018; 40():11-16. PubMed ID: 28887793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New variant in the ALG13 gene responsible for the congenital disorder of Is-type glycosylation in a male patient].
    Ramírez-Montaño D; Candelo E; Pachajoa H
    Andes Pediatr; 2021 Oct; 92(5):769-776. PubMed ID: 35319586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Analysis of the Effect of Asn107Ser Mutation on Alg13 Activity and Alg13-Alg14 Complex Formation and Expanding the Phenotypic Variability of ALG13-CDG.
    Mitusińska K; Góra A; Bogdańska A; Rożdżyńska-Świątkowska A; Tylki-Szymańska A; Jezela-Stanek A
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing.
    Gadomski TE; Bolton M; Alfadhel M; Dvorak C; Ogunsakin OA; Nelson SL; Morava E
    Am J Med Genet A; 2017 Oct; 173(10):2772-2775. PubMed ID: 28777499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Infantile Epileptic Encephalopathy In Asparagine-Linked Glycosylation Thirteen (ALG13) Gene Defect And Dramatic Response With Ketogenic Diet.
    Chand P; Sulaiman A; Angez M; Kirmani S
    J Pak Med Assoc; 2023 Jul; 73(7):1521-1523. PubMed ID: 37469072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes in ALG13-Congenital Disorder of Glycosylation.
    Shah R; Johnsen C; Pletcher BA; Edmondson AC; Kozicz T; Morava E
    Am J Med Genet A; 2023 Jun; 191(6):1626-1631. PubMed ID: 36930724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congenital disorders of glycosylation type IIb with MOGS mutations cause early infantile epileptic encephalopathy, dysmorphic features, and hepatic dysfunction.
    Anzai R; Tsuji M; Yamashita S; Wada Y; Okamoto N; Saitsu H; Matsumoto N; Goto T
    Brain Dev; 2021 Mar; 43(3):402-410. PubMed ID: 33261925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.
    Timal S; Hoischen A; Lehle L; Adamowicz M; Huijben K; Sykut-Cegielska J; Paprocka J; Jamroz E; van Spronsen FJ; Körner C; Gilissen C; Rodenburg RJ; Eidhof I; Van den Heuvel L; Thiel C; Wevers RA; Morava E; Veltman J; Lefeber DJ
    Hum Mol Genet; 2012 Oct; 21(19):4151-61. PubMed ID: 22492991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.
    Ng BG; Sosicka P; Agadi S; Almannai M; Bacino CA; Barone R; Botto LD; Burton JE; Carlston C; Chung BH; Cohen JS; Coman D; Dipple KM; Dorrani N; Dobyns WB; Elias AF; Epstein L; Gahl WA; Garozzo D; Hammer TB; Haven J; Héron D; Herzog M; Hoganson GE; Hunter JM; Jain M; Juusola J; Lakhani S; Lee H; Lee J; Lewis K; Longo N; Lourenço CM; Mak CCY; McKnight D; Mendelsohn BA; Mignot C; Mirzaa G; Mitchell W; Muhle H; Nelson SF; Olczak M; Palmer CGS; Partikian A; Patterson MC; Pierson TM; Quinonez SC; Regan BM; Ross ME; Guillen Sacoto MJ; Scaglia F; Scheffer IE; Segal D; Singhal NS; Striano P; Sturiale L; Symonds JD; Tang S; Vilain E; Willis M; Wolfe LA; Yang H; Yano S; Powis Z; Suchy SF; Rosenfeld JA; Edmondson AC; Grunewald S; Freeze HH
    Hum Mutat; 2019 Jul; 40(7):908-925. PubMed ID: 30817854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could distal variants in ALG13 lead to atypical clinical presentation?
    Accogli A; Radenkovic S; Ranatunga W; Ligezka AN; Rivière JB; Morava E; Trakadis Y
    Eur J Med Genet; 2022 Apr; 65(4):104473. PubMed ID: 35240324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy.
    Kimizu T; Takahashi Y; Oboshi T; Horino A; Koike T; Yoshitomi S; Mori T; Yamaguchi T; Ikeda H; Okamoto N; Nakashima M; Saitsu H; Kato M; Matsumoto N; Imai K
    Brain Dev; 2017 Mar; 39(3):256-260. PubMed ID: 27743886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.
    Vals MA; Ashikov A; Ilves P; Loorits D; Zeng Q; Barone R; Huijben K; Sykut-Cegielska J; Diogo L; Elias AF; Greenwood RS; Grunewald S; van Hasselt PM; van de Kamp JM; Mancini G; Okninska A; Pajusalu S; Rudd PM; Rustad CF; Salvarinova R; de Vries BBA; Wolf NI; ; Ng BG; Freeze HH; Lefeber DJ; Õunap K
    J Inherit Metab Dis; 2019 May; 42(3):553-564. PubMed ID: 30746764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation.
    Helander A; Stödberg T; Jaeken J; Matthijs G; Eriksson M; Eggertsen G
    Mol Genet Metab; 2013 Nov; 110(3):342-4. PubMed ID: 23890587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALG12-CDG: novel glycophenotype insights endorse the molecular defect.
    Sturiale L; Bianca S; Garozzo D; Terracciano A; Agolini E; Messina A; Palmigiano A; Esposito F; Barone C; Novelli A; Fiumara A; Jaeken J; Barone R
    Glycoconj J; 2019 Dec; 36(6):461-472. PubMed ID: 31529350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis.
    Wang Y; Tan J; Sutton-Smith M; Ditto D; Panico M; Campbell RM; Varki NM; Long JM; Jaeken J; Levinson SR; Wynshaw-Boris A; Morris HR; Le D; Dell A; Schachter H; Marth JD
    Glycobiology; 2001 Dec; 11(12):1051-70. PubMed ID: 11805078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.